387 related articles for article (PubMed ID: 17210940)
1. Interpreting the economic literature in oncology.
Grusenmeyer PA; Wong YN
J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
3. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.
Jewell EL; Kulasingam S; Myers ER; Alvarez Secord A; Havrilesky LJ
Gynecol Oncol; 2007 Dec; 107(3):532-40. PubMed ID: 17900674
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analyses in gynecologic oncology: methodological quality and trends.
Manuel MR; Chen LM; Caughey AB; Subak LL
Gynecol Oncol; 2004 Apr; 93(1):1-8. PubMed ID: 15047206
[TBL] [Abstract][Full Text] [Related]
6. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
7. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
Aletti GD; Podratz KC; Moriarty JP; Cliby WA; Long KH
Gynecol Oncol; 2009 Jan; 112(1):16-21. PubMed ID: 19027146
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
10. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis.
Greving JP; Vernooij F; Heintz AP; van der Graaf Y; Buskens E
Gynecol Oncol; 2009 Apr; 113(1):68-74. PubMed ID: 19176236
[TBL] [Abstract][Full Text] [Related]
11. [Methodology of economic assessment: example in oncology].
Jaisson-Hot I; Schott AM; Clippe C; Ganne C; Hajri T; Poncet B; Trillet-Lenoir V; Colin C
Bull Cancer; 2003 Nov; 90(11):939-45. PubMed ID: 14706896
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of cancer treatment costs: another tool for oncology managers.
Chirikos TN; Ruckdeschel JC; Krischer JP
J Oncol Manag; 2001; 10(3):11-7. PubMed ID: 11548179
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
14. Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective.
Bines J; Eniu A
Cancer; 2008 Oct; 113(8 Suppl):2353-8. PubMed ID: 18837028
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics of amifostine in ovarian cancer.
Calhoun EA; Bennett CL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):102-7. PubMed ID: 10348268
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis in oncology.
Evans WK
Praxis (Bern 1994); 2000 Mar; 89(12):492-6. PubMed ID: 10771589
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of community-based physical activity interventions.
Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
20. Costs and cost-effectiveness of colorectal cancer prevention and therapy.
Schrag D; Weeks J
Semin Oncol; 1999 Oct; 26(5):561-8. PubMed ID: 10528905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]